Junshi Biosciences reported total revenue of approximately RMB2,498 million in 2025, a 28% increase year-over-year, driven by toripalimab sales growth. Absci Corporation announced it will report fourth quarter and full year 2025 financial results on March 24, 2026.
The FDA has accepted for review Beren Therapeutics' NDA for adrabetadex in infantile-onset Niemann-Pick disease type C with a PDUFA date of August 17, 2026, and Dr. Reddy's BLA for a biosimilar to Orencia (abatacept).
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07267338 |
Pembrolizumab + MRGOO3 as Neoadjuvant in NPC |
NOT_YET_RECRUITING | PHASE2 |
| NCT06719479 |
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.). |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT04945421 |
IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC |
COMPLETED | PHASE1 |
| NCT03973723 |
Plasma EBV DNA Monitoring in Post-treatment NPC Patients |
COMPLETED | |
| NCT03919552 |
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma |
RECRUITING | PHASE3 |
| NCT03734809 |
NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT03352778 |
IMRT vs 2DRT for NPC Patients |
COMPLETED | |
| NCT03158324 |
Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 |
UNKNOWN | PHASE2 |
| NCT01744587 |
Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients |
COMPLETED | NA |
